Assignee
CANBAS CO LTD
JP·12 granted patents·1 pending application·59 citations·filing 2000–2022
Top patents by PatentIndex Score
13 records- 0188US7125842B2Anti-fungal compounds and methods of useCANBAS CO LTD·Filed 2004·Granted Oct 24, 2006·41 cites·61 claims
- 0277US6881575B1Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agentsCANBAS CO LTD·Filed 2000·Granted Apr 19, 2005·6 cites·5 claims
- 0376US7407985B2Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatmentsCANBAS CO LTD·Filed 2006·Granted Aug 5, 2008·2 cites·27 claims
- 0475US6995135B2Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatmentsCANBAS CO LTD·Filed 2003·Granted Feb 7, 2006·7 cites·40 claims
- 0564US7851592B2Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agentsCANBAS CO LTD·Filed 2004·Granted Dec 14, 2010·0 cites·19 claims
- 0663US7629364B2Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatmentsCANBAS CO LTD·Filed 2008·Granted Dec 8, 2009·0 cites·27 claims
- 0763US7358046B2Sensitivity test to predict efficacy of anti-cancer therapiesCANBAS CO LTD·Filed 2004·Granted Apr 15, 2008·2 cites·2 claims
- 0862US9221872B2Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulationsCANBAS CO LTD·Filed 2014·Granted Dec 29, 2015·1 cites·50 claims
- 0957US7652042B2Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatmentsCANBAS CO LTD·Filed 2008·Granted Jan 26, 2010·0 cites·33 claims
- 1053US12239714B2Phosphatidylserine-binding conjugatesCANBAS CO LTD·Filed 2022·Granted Mar 4, 2025·0 cites·22 claims
- 1147US7030111B2Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatmentsCANBAS CO LTD·Filed 2003·Granted Apr 18, 2006·0 cites·28 claims
- 1243US10149887B2Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatmentCANBAS CO LTD·Filed 2016·Granted Dec 11, 2018·0 cites·35 claims
- 1328US2016061841A1Nrf2-based cancer treatment and detection methods and usesCANBAS CO LTD·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CANBAS CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →